Great interview with PH the man, the myth the legend! A good insight into how Paul finds and licenses opportunities with his deep network within Cancer institutions all over the world..
Special note: The last question about CHM highlights the interest in the CHM IPO being 3x oversubscribed (20c) so IMO plenty of people wanting more of the raise will be looking to get in early at de-risk events. He also highlights the importance of data doing all the work in the growth of the company and the timing in licensing something already in Phase I. He stresses how lucky he was to snap up CLTX from city of hope. And comments on while its important to show pre-clinical data and mouse trials, it means nothing as in human is significantly different and that needs to be validated.
CHM Price at posting:
31.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)